1,150
Participants
Start Date
July 31, 2008
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Semuloparin sodium
"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
Enoxaparin
"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
Placebo
"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Buenos Aires
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park
Sanofi-Aventis Administrative Office, Minsk
Sanofi-Aventis Administrative Office, Laval
Sanofi-Aventis Administrative Office, Bogotá
Sanofi-Aventis Administrative Office, Prague
Sanofi-Aventis Administrative Office, Hørsholm
Sanofi-Aventis Administrative Office, Tallinn
Sanofi-Aventis Administrative Office, Athens
Sanofi-Aventis Administrative Office, Vilnius
Sanofi-Aventis Administrative Office, México
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Bucharest
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Midrand
Sanofi-Aventis Administrative Office, Kiev
Lead Sponsor
Sanofi
INDUSTRY